Counterpoint: Data first.
Golub
Todd
T
Cancer Program at the Broad Institute, Cambridge, Massachusetts 02142, USA. golub@broadinstitute.org
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides; D055808:Drug Discovery / Q000379:methods / Q000639:trends*; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D015894:Genome, Human / Q000235:genetics*; D023281:Genomics / Q000639:trends; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D057285:Precision Medicine / Q000639:trends; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl